文献速递艾滋病与性传播感染

干血斑中替诺福韦二磷酸与HIV感染者病毒抑制强烈相关

Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
PubMed 文献 · Clin Infect Dis · 2019-01-01

研究在532名接受替诺福韦二吡呋酯(TDF)为基础治疗的HIV感染者中,于48周内最多采集3次干血斑(DBS)检测替诺福韦二磷酸(TFV-DP)。基线病毒学抑制者中,TFV-DP在黑人、非增强方案及非核苷类逆转录酶抑制剂方案中较低。调整混杂后,TFV-DP≥1850 fmol/punch相比<350 fmol/punch的病毒抑制aOR为73.5(95%CI 25.7-210.5;P<.0001)。

要点

  • 基线病毒学抑制者中,黑人TFV-DP几何均值1453(95%CI 1291-1635)低于白人1793(95%CI 1678-1916),P=.002。
  • 非增强方案TFV-DP几何均值1610(95%CI 1505-1723)低于增强方案1888(95%CI 1749-2037),P=.002。
  • 调整后TFV-DP≥1850 fmol/punch相比<350 fmol/punch的病毒抑制aOR为73.5(95%CI 25.7-210.5;P<.0001)。

核心结论

  • 在接受TDF为基础治疗的HIV感染者中,干血斑TFV-DP与病毒学抑制强烈相关,并与某些参与者特征相关。
  • 需要进一步研究以评估该药物依从性和暴露指标在临床实践中的应用。

研究设计与样本

  • 在532名接受TDF为基础治疗的HIV感染者中,48周内最多采集3次干血斑检测TFV-DP,共分析1199份干血斑。
  • 参与者中76名为女性,101名为黑人,101名为西班牙裔。
  • 使用t检验或方差分析比较对数转换的基线TFV-DP,采用广义估计方程估算病毒抑制(<20拷贝/mL)的调整比值比(aOR)。

主要发现

  • 基线病毒学抑制者(n=347)中,黑人TFV-DP几何均值1453(95%CI 1291-1635)低于白人1793(95%CI 1678-1916),P=.002;也低于西班牙裔1760(95%CI 1563-1982),P=.025。
  • 非增强方案TFV-DP几何均值1610(95%CI 1505-1723)低于增强方案1888(95%CI 1749-2037),P=.002。
  • 非核苷类逆转录酶抑制剂为基础方案TFV-DP几何均值1563(95%CI 1432-1707)低于增强蛋白酶抑制剂为基础方案1890(95%CI 1704-2095),P=.006;也低于多类方案1927(95%CI 1650-2252),P=.022。
  • 调整年龄、性别、种族、体重指数、估算肾小球滤过率、CD4+ T细胞计数、抗逆转录病毒药物类别和治疗持续时间后,TFV-DP≥1850 fmol/punch相比<350 fmol/punch的病毒抑制aOR为73.5(95%CI 25.7-210.5;P<.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以评估该药物依从性和暴露指标在临床实践中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility in human immunodeficiency virus (HIV) treatment remains unknown. METHODS: DBS for TFV-DP were collected up to 3 times over 48 weeks in persons living with HIV (PLWH) who were receiving TFV disoproxil fumarate (TDF)-based therapy. Log-transformed baseline TFV-DP was compared using t-tests or analyses of variance; generalized estimating equations were used to estimate the adjusted odds ratio (aOR) of viral suppression (<20 copies/mL) based on the TFV-DP concentration at the study visit. RESULTS: We analyzed 1199 DBS from 532 participants (76 female; 101 Black, 101 Hispanic). Among the virologically-suppressed participants at baseline (n = 347), TFV-DP was lower in Blacks (geometric mean 1453, 95% confidence interval [CI] 1291-1635) vs Whites (1793, 95% CI 1678-1916; P = .002) and Hispanics (1760, 95% CI 1563-1982; P = .025); in non-boosted (1610, 95% CI 1505-1723) vs. boosted (1888, 95% CI 1749-2037; P = .002) regimens; and in non-nucleoside reverse transcription inhibitor-based (1563, 95% CI 1432-1707) vs. boosted protease inhibitor-based (1890, 95% CI 1704-2095; P = .006) and multiclass-based (1927, 95% CI 1650-2252; P = .022) regimens. The aOR of virologic suppression, after adjusting for age, gender, race, body mass index, estimated glomerular filtration rate, CD4+ T-cell count, antiretroviral drug class and duration of therapy, was 73.5 (95% CI 25.7-210.5; P < .0001) for a TFV-DP concentration ≥1850 fmol/punch compared to <350 fmol/punch. CONCLUSIONS: TFV-DP in DBS is strongly associated with virologic suppression in PLWH on TDF-based therapy and is associated with certain participant characteristics. Further research is required to evaluate this drug adherence and exposure measure in clinical practice. CLINICAL TRIALS REGISTRATION: NCT02012621.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Castillo-Mancilla JR, Morrow M, Coyle RP, et al. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. Clin Infect Dis. 2019. PMID: 30137238. doi:10.1093/cid/ciy708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。